precisionmedicineonline8h
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
precisionmedicineonline23h
After Success in Treating Cancer, CAR T Cells Break Into Autoimmune, HIV, and More
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
precisionmedicineonline4h
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
precisionmedicineonline10h
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
precisionmedicineonline12h
Giostar Gearing up for Phase II Trial of Type 2 Diabetes Stem Cell Therapy in US
The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.
precisionmedicineonline10h
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
precisionmedicineonline10h
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.